A study to check whether Dermapen 4 microneedling device with MG-CLR serum reduces acne in female subjects.

A full face, baseline-controlled study to evaluate the efficacy of Dermapen 4 microneedling device in conjunction with MG-CLR serum for acne treatment over 12 weeks. - NIL

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/03/082326

Enrollment

Registered

2025-03-17

Start date

Unknown

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: Dermapen 4 microneedling device with MG-CLR serum.: Treatment using Dermapen 4 microneedling device with MG-CLR serum will be provided at baseline, week 2, week 4 and week 6 to evalua

Eligibility

Inclusion criteria

Inclusion criteria: 1. Female subjects aged between 18-45 years (both ages inclusive). 2. Subjects having IGA score of 2 and 3

Exclusion criteria

Exclusion criteria: 1. Subjects with known skin condition that may impact the assessment. 2. Subjects with active Herpes labialis infection. 3. Subjects known to have bleeding and clotting disorders (self-declared). 4. Subjects known to have connective tissue disorders. 5. Subjects with any other signs of significant local irritation or skin disease. 6. Subjects currently taking any medication, which the investigator believes may influence the interpretation of the data. 7. Subjects having clinically significant systemic or cutaneous disease, chronic illness or major surgery in the last year. 8. Subjects undergoing treatment of any skin condition on their face.

Design outcomes

Primary

Measure	Time frame
Change in acne severity using the modified GAGS scale at all time points when compared to baselineTimepoint: Baseline, week 2, week 4, week 6 and week 12.	—

Secondary

Measure	Time frame
1.Change in acne count, IGA score and IGAI scores at all time points compared to baseline. 2. to prove that Dermapen 4 with MG-CLR serum does not aggravate acne severity. 3. Subject self assessment and self satisfaction questionnnaires.Timepoint: Baseline, week 2, week 4, week 6 and week 12.	—

Countries

India

Contacts

Public ContactSudhanthiran S

MS Clinical Research Pvt. Ltd.

ritambhara@msclinical.com8040917253

Outcome results